STOCKHOLM — Trial results are demonstrating positive findings for a single intravitreal injection gene therapy for patients with neovascular age-related macular degeneration (nAMD) who previously ...

AbbVie and RemeGen are the first companies to announce a deal at the J.P Morgan Healthcare Conference 2026, with more deals ...

The study found significant intra-group CMT reductions in the DEX-I group, with a higher percentage reduction than the ...

Continuing anti-vascular endothelial growth factor (VEGF) therapy plus chemotherapy in the second-line setting led to a small but nonsignificant increase in overall survival in patients with ...

Please provide your email address to receive an email when new articles are posted on . SEATTLE — In this Healio Video Perspective from the ARVO meeting, Jennifer I. Lim, MD, discusses anti-VEGF ...

A single intravitreal injection of UBX1325 (foselutoclax) was shown to be safe in patients with diabetic macular edema. The drug also showed potential efficacy in patients who failed to optimally ...

Patients assigned to SRT received an average of 10.7 doses of ranibizumab (Lucentis) over 2 years as compared with 13.3 for patients assigned to sham SRT. Best-corrected visual acuity (BCVA) did not ...

Add Yahoo as a preferred source to see more of our stories on Google. Hutchmed's fruquintinib and Eli Lilly & Innovent Biologics' Tyvyt (sintilimab) significantly improved PFS during a Phase III trial ...

The dual inhibition of PD-1 and VEGF pathways by ivonescimab aims to enhance immune response and limit tumor angiogenesis, ...